Navigation Links
Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
Date:4/16/2008

UCB announces clinical data presented at the 60th Annual Meeting of the

American Academy of Neurology (AAN) in Chicago

SMYRNA, Ga., April 16 /PRNewswire/ -- UCB presented efficacy and safety results from pooled analyses of Phase II and III double-blind, randomized, placebo-controlled clinical trials investigating lacosamide for the treatment of diabetic neuropathic pain. These data, which were presented at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago, showed that lacosamide significantly reduced pain in patients with diabetic neuropathic pain and was generally well-tolerated.

Lacosamide is currently under review with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of diabetic neuropathic pain and as adjunctive therapy for the treatment of partial onset seizures in adults with epilepsy.

"Neuropathy can be a painful and potentially debilitating complication of diabetes, and there is still a need for new treatment options," said Aziz Shaibani, M.D., F.A.C.P., lacosamide clinical investigator and director of the Nerve and Muscle Center of Texas in Houston. "These data showed that lacosamide reduced pain in patients with diabetic neuropathic pain and was generally well-tolerated."

Pooled Efficacy Analysis

Primary efficacy was evaluated among patients treated with 400 mg/day of lacosamide by examining the change in average daily pain score, from baseline to the last four weeks of maintenance in three Phase III, fixed-dose trials (SP742, SP743, SP768) and from baseline through the entire maintenance period in one Phase II, flexible-dose trial (SP614). The pain score was based on an 11-point Likert Scale ranging from zero (no pain) to 10 (worst possible pain).

The mean reduction in pain score reached the level of statistical significance in SP614, SP742 and SP768 (p=0.039, 0.01 and 0.0507, respectively). Significance was not
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2008)...ase of Test Development Program, ORANGE COUNTY, C...oulter, Inc. (NYSE: BEC ) announced today that it...bligation to Nephromics LLC, a Chestnut Hill,Mass...ense is for tests,related to the detection, monito...g cause of maternal death. In addition, Beckman Co...
(Date:8/18/2008)...re-FirstCall/ -- Micromet, Inc.,(Nasdaq: MITI ), ...rietary,antibodies for the treatment of cancer, in...bcast and conference call this morning, Monday,Au...m. Central European,Time) to discuss the blinatumo...E on August 15, 2008., To access the webcast and ...
(Date:8/14/2008)...irstCall/ -- AstraZeneca (NYSE: AZN ),today annou...al Cancer,Centre Singapore (NCCS) and the National...compounds. The collaboration, which is spelt out i...ned today, aims to further,build AstraZeneca,s dru...speed up access to new medicines of potential bene...
(Date:8/14/2008)...TE) showing clinical benefit in cancer,patients; B...ize and attack cancer...all/ -- Micromet, Inc.,(Nasdaq: MITI ), a biophar...ntibodies for the treatment of cancer, inflammatio...tion of a Phase 1 clinical study(1) on its,BiTE(R)...
Breaking Medicine Technology:Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers 2Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 2AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 5AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 6Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 11176 1HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 11176 2Oncology Metrics Launches the National Practice Benchmark 3A One in a Series of Initiatives to Help Community Oncology Practices Better Measure Operat 11172 1Oncology Metrics Launches the National Practice Benchmark 3A One in a Series of Initiatives to Help Community Oncology Practices Better Measure Operat 11172 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 1Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 3Massive American Red Cross Tornado Relief Effort Spans Five States 11169 1Massive American Red Cross Tornado Relief Effort Spans Five States 11169 2
...s large multi-site lab faced challenges with manua...agement challenges which were exacerbated by staf...ized that better document control was essential fo...r laboratorians to more efficiently access and man...f Quality Management software packages and evaluat...
...Editor ,According to the American Diabetes Ass...es in 2002 was estimated to be $132 billion, or on... United States. A chronic disease with no cure, di...ype 2, and gestational) marked by high levels of b...duction, insulin action, or both. Nearly 20 millio...
Other Medicine Technology:Choosing Lab Quality Management Software 2Choosing Lab Quality Management Software 3Choosing Lab Quality Management Software 4Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control 2Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control 3
(Date:8/20/2008)...Newswire/ -- The National Alliance on,Mental Illne...tes on mental,health services and invites the publ...rding it to others., The survey is available at ...udes a version in Spanish., In 2006, NAMI,s "Grad...hcare System for Serious Mental Illnesses" (http:...
(Date:8/20/2008)... calorie-burning brown fat can be produced experim...ses the prospect of new ways to fight obesity and ... Institute. , Reporting in the Aug. 21 issue of ... that brown fat, which is known as the "good" form... releases energy, unlike "bad" white fat that simp...
(Date:8/20/2008)...rth is part of a new generation of neurosurgeons w...ts. , At Loyola University Hospital, Duckworth i... to repair life-threatening aneurysms and to drama...Rather than removing large sections of the skull o...ch smaller openings. And in certain cases, he goes...
(Date:8/20/2008)...rn calories, hints of new ways to treat obesity ,...- A protein that induces bone growth also helps pr...urn calories and plays a role in fighting obesity,... Boston. , They said their finding about the pr...prevent and treat obesity. , The two main types...
Breaking Medicine News(10 mins):Health News:Grading the States; Mental Health Services Survey 2Health News:Making 'good' fat from muscle and vice versa 2Health News:Making 'good' fat from muscle and vice versa 3Health News:Brain surgery is getting easier on patients 2Health News:Brain surgery is getting easier on patients 3Health News:Bone Growth Protein Also Promotes 'Good' Fat 2
...a, high blood pressure or depression are more like...earchers at the University of Texas,// have survey...ars of age. They found that the partners of those ... per cent more likely to have these problems thems...
... could soon be procurable in the doctor's office o...drug responses. Researchers at LGC// (Laboratory o...duce a DNA test kit which uses saliva, blood or ur...n 15 to 20 minutes. The device has been made smal...
...f Texas feel that they may have found an effective...hat threatens clear vision.// Using photodynamic t...n three patients who were suffering from intraocul...ed serious retinal detachments. Intraocular choroi...
... observed that nearly one out of every five medica...s may be in error. The problem occurs regardless o...e nation's leading health care accrediting organiz...ne released a report titled, "To Err is Human: Bui...
Other Medicine News:
...r is a multi-lumen, over-the-wire thrombectomy cat...al of fresh, soft thrombus in dialysis shunts. The...y alternative to surgery and thrombolytic therapy....jector. Fragments and removes thrombus to help re...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system.
...tomy catheter is designed to offer the ultimate in...eate a low pressure zone around the catheter tip c... catheter, where it is fragmented by the jets, and...vides rapid restoration of flow in minutes, as opp...
When combined with a stimulation lead system, the Model 3077 SSI Temporary Pacemaker can be used whenever temporary atrial or ventricular pacing is indicated. The device can be employed for therapeut
Medicine Products: